Wockhardt Posts PAT of Rs. 107 Cr for Q1 FY27 as Biotech Portfolio Drives Growth

Wockhardt Posts PAT of Rs. 107 Cr for Q1 FY27 as Biotech Portfolio Drives Growth​

Wockhardt Limited, a global pharmaceutical and biotechnology company, announced its first-quarter results for the financial year 2026-27. The company reported Profit After Tax (PAT) of Rs. 107 crore for the quarter ended June 30, 2026.

The consolidated Q1 FY27 performance showed significant momentum, with revenue growing by 26% compared to the previous year. Revenue reached Rs. 929 crore in Q1 FY27, up from Rs. 738 crore in the corresponding period of the prior year. EBITDA grew strongly by 86%, hitting Rs. 188 crore against a previous figure of Rs. 101 crore.

The company’s portfolio highlights the increasing contribution of its innovative offerings, with Biotechnology products contributing 27% of the revenue in Q1 FY27.

Financial Highlights Overview​

Wockhardt reported strong profitability metrics across several periods:

Global and Regional Performance​

The company's regional revenue demonstrated robust growth in Q1 FY27, with the Emerging Markets region leading the charge.

The regional breakdown is as follows:


Key regional observations include:

• The India Branded Business reached Rs. 156 crore in Q1 FY27, reflecting a growth of 21% compared to the previous year. This was attributed to performance from Diabetic therapy, NCE (EMROK), and the introduction of the Regenerative Derma segment.
• The Emerging Markets region posted Rs. 263 crore in Q1 FY27, representing a 64% growth versus the prior year. The Biotech Insulin segment was cited as the primary driver for this strong performance, with operations in Latam contributing significantly to the growth.
• The UK region revenue stood at Rs. 343 crore in Q1 FY27, showing a 10% increase compared to the previous year.

Biosimilar and R&D Focus Areas​

In Biosimilar Highlights, the Biotech operations recorded revenues of Rs. 236 crore for the quarter, marking a 112% growth versus Q1 FY26. This performance is supported by the Emerging Market biotech segment, which grew by approximately 146% on Q1 FY26, fueled by strategic business partnerships and new deals in markets such as Brazil, Thailand, Egypt, Algeria, and LATAM.

The company highlighted its strong end to end integrated Biotech infrastructure, noting that future opportunities include the upcoming launch of Insulin analogs, which aims to advance leadership in diabetes care globally.

Novel Antibiotics and Product Pipeline​

Wockhardt reported completing Phase 3 Clinical Trials for five novel antibiotics: Emrok®, Emrok O®, Miqnaf®, Zaynich®, and Foviscu®.

ZAYNICH® Highlights:

• The drug was approved by the US FDA on May 28, 2026, for treating cUTI including Pyelonephritis, making it an India discovery and developed drug gaining US FDA approval. The EMA review process is ongoing, with the EMA stating that the submitted dossier is adequate for review across multiple indications (cUTI, cIAI, HAP/VAP, BSI).
• CDSCO Subject Expert Committee approved the clinical data on March 10, 2026, with full approval expected by Q3 FY27 after CMC data review.

EMROK ® / EMROK O ®:
* These products registered a growth rate of 29% versus the previous year's Q1 FY27. They continue to address critical unmet needs in treating difficult-to-manage Grampositive infections, including bone and joint infections, diabetic foot infections, and pneumonia.

MIQNAF® NAFITHROMYCIN:
* This product has been approved and launched in India following the removal of the 'supply condition' by DCGI, which now facilitates marketing access to a wider patient population.

FOVISCU® (WCK 4282):
* India Phase 3 Clinical Trial for Foviscu successfully concluded, with an NDA Filing planned during Q3 FY27. The combined Phase 2 and Phase 3 program involved 324 hospitalized cUTI and AP patients, noting that over half (51%) of the Enterobacterales isolates were ESBL-positive.

Intellectual Property and Global Status​

In terms of intellectual property, one patent was filed during Q1 FY27. The company maintains a cumulative total of 859 patents, with 3291 filings made to date. Wockhardt is highlighted as the only company globally where US FDA has provided QIDP Status (Qualified Infectious Disease Product) for six of its Anti-bacterial discovery programs: three Gram Negative and three Gram Positive types effective against untreatable Superbugs.

WOCKPHARMA Stock Price Movement​

Shares of Wockhardt Limited today slipped by 2.87% to settle at ₹1931.2, reflecting a sharp move in the pharmaceutical sector. The stock traded with a volume of 1.70 million shares as the market closed.